All follow-up parameters included follow-up duration, interval from CRVO onset to first IVT, IVTs of anti-vascular endothelial growth factor medicine, IVTs of dexamethasone implant, total number of IVTs, retinal photocoagulation treatment, IOL implantation, OHT event within follow-up duration, BCVA at first visit, 1-month BCVA after first IVT, lowest central retinal thickness within follow-up duration, BCVA at the final visit, low vision, blindness, and NVG. The gene discussed is VEGFA; the disease is Blindness.